TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18333866

Group type: EXPERIMENTAL
Intervention: efavirenz + Combivir (lamivudine/zidovudine)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: efavirenz + didanosine + tenofovir
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: nevirapine + lamivudine + tenofovir
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir) + stavudine + lamivudine
Number of subjects: 29
Study: 15672015

Group type: EXPERIMENTAL
Intervention: Glyburide (low dose ≤10 mg)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Glyburide (high dose >10 mg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Glyburide and Insulin
Number of subjects: 404
Study: 12024844

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy (GLC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 50
Study: 10863393

Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation plus TTC‐HCl (test 1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation plus TTC‐HCl plus trypsin solution after extraction (test 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Periodontal instrumentation alone (control 1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Periodontal instrumentation plus trypsin solution after extraction (control 2)
Number of subjects: 22
Study: 7499781

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 600 mg per day for 2 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1940092

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waiting List control group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (after 4 months)
Number of subjects: 101
Study: 7250177

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison to normal subjects
Number of subjects: 6
Study: 31986315

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 33
Study: 31863046

Group type: EXPERIMENTAL
Intervention: Glass ionomer (GI) restorations
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Composite resin (CR) restorations
Number of subjects: 59
Study: 28459163

Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Mirror therapy + neuromuscular electrical stimulation
Number of subjects: 69
Study: 26897778

Group type: EXPERIMENTAL
Intervention: Thickened formula (corn flour starch)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Un-thickened formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Thickened formula
Number of subjects: 15
Study: 23564205

Group type: EXPERIMENTAL
Intervention: ATRA with Daunorubicin (DNR) and AraC (AraC group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATRA with DNR but without AraC (no AraC group)
Number of subjects: 0
Study: 21615299

Group type: EXPERIMENTAL
Intervention: 5% albumin solution (albumin-bolus group)
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: 0.9% saline solution (saline-bolus group)
Number of subjects: 3141

Group type: COMPARATOR
Intervention: No bolus (control group)
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: Any bolus (albumin or saline)
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: Albumin-bolus group (stratum B)
Number of subjects: 3141

Group type: EXPERIMENTAL
Intervention: Saline-bolus group (stratum B)
Number of subjects: 3141
Study: 19408724

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (40 mg/ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b (15 x 10(5) U/ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil (2.5 mg/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated keloid and hypertrophic scar, normal skin
Number of subjects: 12
Study: 17218799

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gabapentin (0 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cocaine doses (0, 12, 25, 50 mg)
Number of subjects: 12
Study: 15020609

Group type: EXPERIMENTAL
Intervention: PSC-MEC (valspodar plus mitoxantrone, etoposide, and cytarabine)
Number of subjects: 129

Group type: COMPARATOR
Intervention: MEC (mitoxantrone, etoposide, and cytarabine)
Number of subjects: 129
Study: 12047397

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9400485

Group type: EXPERIMENTAL
Intervention: Pyeloplasty
Number of subjects: 32

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 32
Study: 8083675

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2708468

Group type: EXPERIMENTAL
Intervention: Aggressive boys in experimental conditions exposed to angry interactions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High responders from the aggressive group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (nonaggressive boys)
Number of subjects: 40
Study: 342318

Group type: COMPARATOR
Intervention: Vaccine with 6 log EID50/dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine with 7 log EID50/dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31728681

Group type: EXPERIMENTAL
Intervention: Resistant dextrin (10 g/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31241488

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 29114781

Group type: EXPERIMENTAL
Intervention: Direct observation of once-weekly isoniazid and rifapentine
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Self-administration of once-weekly isoniazid and rifapentine
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Self-administration with reminders of once-weekly isoniazid and rifapentine
Number of subjects: 1002
Study: 25457496

Group type: EXPERIMENTAL
Intervention: Screening arm (RP or RT)
Number of subjects: 2595

Group type: COMPARATOR
Intervention: Control arm (RT with hormonal therapy, dosage ≥69Gy)
Number of subjects: 2595

Group type: COMPARATOR
Intervention: Control arm (RT with hormonal therapy)
Number of subjects: 2595
Study: 22751219

Group type: EXPERIMENTAL
Intervention: Milwaukee brace
Number of subjects: 10
Study: 21484386

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block until postoperative day 7 (POD 7)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Continuous femoral nerve block until postoperative day 3 (POD 3)
Number of subjects: 63
Study: 18565968

Group type: EXPERIMENTAL
Intervention: PRAV+IRB (pravastatin 40 mg/day + irbesartan 300 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PRAV (pravastatin 40 mg/day)
Number of subjects: 60
Study: 16336332

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 2340
Study: 12478101

Group type: EXPERIMENTAL
Intervention: HM3
Number of subjects: 167

Group type: COMPARATOR
Intervention: Lithostar Plus
Number of subjects: 167
Study: 10730982

Group type: EXPERIMENTAL
Intervention: Oxytocin (1.9 mg/d) continuous infusion from Days 14 to 26 after estrus
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control (Group 1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline pregnant (Group 3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxytocin (Group 2)
Number of subjects: 12
Study: 8774294

Group type: EXPERIMENTAL
Intervention: Split-dose hMG (150 IU twice daily)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Single-dose hMG (300 IU once daily)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Split-dose hMG
Number of subjects: 171

Group type: COMPARATOR
Intervention: Single-dose hMG
Number of subjects: 171
Study: 1590574

Group type: EXPERIMENTAL
Intervention: Propofol administered at 15 mg/kg body weight per hour for 10 min after induction, then reduced to 6 mg/kg body weight per hour
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg before induction with propofol at similar dosage to group I
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg before induction with propofol at an infusion rate of 6 mg/kg body weight from the beginning
Number of subjects: 60
Study: 6204377

Group type: EXPERIMENTAL
Intervention: Physiological saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextranomer beads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porcine skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminium foil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double layer bandage
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study: 30146931

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480
Study: 26453188

Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview (BNI), a 10-15 minute structured interview
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MOTIV), a 30-45 minute intervention
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (received only a list of substance use treatment resources)
Number of subjects: 167
Study: 24958910

Group type: EXPERIMENTAL
Intervention: HPV16/18 bivalent vaccine
Number of subjects: 5404

Group type: COMPARATOR
Intervention: Control (unvaccinated women)
Number of subjects: 5404
Study: 23076429

Group type: EXPERIMENTAL
Intervention: Target fixation (eyes free, pointer guided by foveal vision)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central fixation (eyes fixed straight ahead, pointer guided by peripheral vision)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remembered auditory, visual, and bimodal targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with young adults
Number of subjects: 0
Study: 19628211

Group type: EXPERIMENTAL
Intervention: Presence of at least one epsilon4 allele (epsilon4+)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Addition of epsilon4+ to multivariate ROC model
Number of subjects: 1255
Study: 18561117

Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg once daily
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 17012860

Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib vaccine
Number of subjects: 913

Group type: COMPARATOR
Intervention: Tritanrix HepB/Hiberix (control)
Number of subjects: 913
Study: 12740676

Group type: EXPERIMENTAL
Intervention: Lower molecular weight hyaluronic acid plus physical therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Higher molecular weight hyaluronic acid plus physical therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 37
Study: 11763934

Group type: EXPERIMENTAL
Intervention: Waxed floss
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Woven floss
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shred-resistant floss
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unwaxed floss
Number of subjects: 24
Study: 9286743

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (1 mg.kg‐1.day‐1) for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8336223

Group type: EXPERIMENTAL
Intervention: Therabite System combined with unassisted exercise
Number of subjects: 3

Group type: COMPARATOR
Intervention: Unassisted exercise
Number of subjects: 3

Group type: COMPARATOR
Intervention: Mechanically assisted mandibular mobilization with stacked tongue depressors combined with unassisted exercise
Number of subjects: 3
Study: 3948042

Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular ketamine (Group I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 10 mg epidural ketamine (Group II)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 mg epidural ketamine (Group III)
Number of subjects: 34
Study: 29462225

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution, once-daily for 48 weeks
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1655
Study: 25834964

Group type: EXPERIMENTAL
Intervention: Etomidate and fentanyl (0.25 mg/kg etomidate, 1.30 μg/kg fentanyl)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ketamine (1.25 mg/kg)
Number of subjects: 44
Study: 24329543

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 960

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 960

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 960
Study: 21594719

Group type: EXPERIMENTAL
Intervention: Walking Program (WA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Muscle-Strengthening Exercises (MS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 90
Study: 19744230

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 18627363

Group type: EXPERIMENTAL
Intervention: 300 mg zidovudine and 150 mg lamivudine B.I.D. for 6 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 59
Study: 16129365

Group type: EXPERIMENTAL
Intervention: Myeloablative megatherapy (melphalan, etoposide, and carboplatin) with autologous stem-cell transplantation (n=149)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Oral maintenance chemotherapy with cyclophosphamide (n=146)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Myeloablative megatherapy
Number of subjects: 295

Group type: COMPARATOR
Intervention: Oral maintenance chemotherapy
Number of subjects: 295
Study: 12820929

Group type: EXPERIMENTAL
Intervention: Iodized salt group
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non‐iodized salt group
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study: 10791213

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 treatment (PG group; n = 19)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 43
Study: 8778905

Group type: EXPERIMENTAL
Intervention: buspirone (30 mg PO)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 1739177

Group type: EXPERIMENTAL
Intervention: Endoscopic cholangiography and stone removal prior to open cholecystectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open cholecystectomy, operative cholangiography, and common duct exploration
Number of subjects: 34
Study: 6143664

Group type: EXPERIMENTAL
Intervention: 100 mg Metoprolol (beta‐1‐selective blockade)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg Bupranolol (non‐selective beta‐blockade)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 31405919

Group type: EXPERIMENTAL
Intervention: Brachyspira aalborgi and Brachyspira pilosicoli isolates cultured and sequenced from individuals with colonic spirochaetosis.
Number of subjects: 745

Group type: COMPARATOR
Intervention: Standard 16S amplicon sequencing using primers for human microbiota studies.
Number of subjects: 745
Study: 28942587

Group type: EXPERIMENTAL
Intervention: benzydamine HCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: sodium bicarbonate
Number of subjects: 60
Study: 26011816

Group type: EXPERIMENTAL
Intervention: Mitiglinide/Voglibose (fixed-dose combination of mitiglinide 10 mg and voglibose 0.2 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glimepiride (0.5 mg)
Number of subjects: 30
Study: 24408751

Group type: EXPERIMENTAL
Intervention: High well-being participants (10% of participants)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Affect balance
Number of subjects: 128
Study: 22260834

Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Adefovir (ADV)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 320
Study: 20527504

Group type: EXPERIMENTAL
Intervention: Colgate Total Pharma (CTP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Colgate Regular Toothpaste (CRT)
Number of subjects: 15
Study: 17672383

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.0 and 2.0 mg/70 kg, orally administered)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25 and 0.50 mg/70 kg, subcutaneously administered)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20
Study: 15689196

Group type: EXPERIMENTAL
Intervention: PC-interactive pressure algesimetry
Number of subjects: 0
Study: 12660838

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 0
Study: 10468801

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral) at a dose of 2.5 mg/kg daily, increased to a maximum of 5 mg/kg daily for a maximum of 12 weeks, followed by either abrupt cessation or tapering off by 1 mg/kg weekly.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral) treatment courses
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral) treatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Neoral)
Number of subjects: 400
Study: 8552462

Group type: EXPERIMENTAL
Intervention: Illuminated frame
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frame added in an illuminated room
Number of subjects: 0
Study: 2286467

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol 3 g single dose
Number of subjects: 158

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg b.i.d. for seven days
Number of subjects: 158
Study: 40485

Group type: EXPERIMENTAL
Intervention: Alfadione (without surgery)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfadione (during surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane (during surgery)
Number of subjects: 20
Study: 31771803

Group type: EXPERIMENTAL
Intervention: Methylphenidate and levodopa/carbidopa
Number of subjects: 101
Study: 30359763

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study: 27658661

Group type: EXPERIMENTAL
Intervention: B&O suppository (15 mg/30 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 71
Study: 25785460

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 98
Study: 23958473

Group type: EXPERIMENTAL
Intervention: 1 g/day sphingomyelin (SM) for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet without sphingomyelin
Number of subjects: 10
Study: 21030684

Group type: EXPERIMENTAL
Intervention: Glycated albumin (GA) assay on fresh samples
Number of subjects: 180

Group type: COMPARATOR
Intervention: Glycated albumin (GA) assay on stored samples
Number of subjects: 180
Study: 19242031

Group type: EXPERIMENTAL
Intervention: Daily IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Twice weekly IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Once weekly IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no IFA supplementation)
Number of subjects: 161
Study: 17900401

Group type: COMPARATOR
Intervention: 10 mg bupivacaine 0.5% intrathecally plus 500 ml Ringer lactate solution (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine 0.5% plus 25 mug fentanyl plus 500 ml Ringer lactate solution (group F)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine 0.5% plus 25 mug fentanyl intrathecally plus 500 ml Gelofusine intravenously (group G)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 mg bupivacaine 0.5% plus 25 mug fentanyl intrathecally plus 500 ml Gelofusine intravenously plus tight wrapping of the lower extremities with an Esmarch bandage (group E)
Number of subjects: 120
Study: 15277930

Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA) - axillary brachial plexus block
Number of subjects: 100
Study: 17108343

Group type: EXPERIMENTAL
Intervention: Epoetin alfa targeted to achieve a hemoglobin level of 13.5 g/dL
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Epoetin alfa targeted to achieve a hemoglobin level of 11.3 g/dL
Number of subjects: 1432
Study: 10888070

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 10
Study: 876794

Group type: EXPERIMENTAL
Intervention: Short incision (2.5 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long incision (4.5 cm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic release
Number of subjects: 0
Study: 1761364

Group type: EXPERIMENTAL
Intervention: IMREG-1
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 6804114

Group type: EXPERIMENTAL
Intervention: Pressurized aerosol formulation of sodium cromoglycate (8 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard sodium cromoglycate powder (80 mg/day)
Number of subjects: 0
Study: 31818059

Group type: EXPERIMENTAL
Intervention: High-velocity elastic-band training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 18
Study: 30192317

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 426
Study: 29907780

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) prior to hand function training, 40 minutes before each session, twice a week for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) prior to hand function training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham Electrical Stimulation (Control)
Number of subjects: 12